Illumina stock reversed higher Tuesday, though China signaled it would ban the importation of the company's gene-mapping products as part of an escalating tariffs battle with President Donald ...

At a launch event on Feb. 20, Roche detailed plans to enter Illumina's sequencing stronghold with a new platform. Roche's platform is in testing now and scheduled to launch commercially in 2026.

Illumina is an applied genomics technology company that was founded in 1998 with the mission statement: ‘To improve human health by unlocking the power of the genome’. Over the past two ...

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...

Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity.

In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against the other large-cap stocks. The big and large-cap stocks have spearheaded the rally in the past ...

RBC Capital reiterated an Outperform rating and $247 price target on Illumina (ILMN) after Roche (RHHBY) presented scientific details about its sequencing by extension technology, with initial ...